AAN responds to IOM statement.

The principal endpoint of ABSORB III is target lesion failure , a combined way of measuring the safety and performance of Absorb compared to the company's XIENCE family of drug eluting stents at twelve months. Related StoriesBoston Children's and Rock Wellness synergy to accelerate development of pediatric health technologiesGlan Clwyd Hospital N Wales invest in Esaote's G-Scan MRI device for weight-bearing scanningACC's public reporting plan provides information regarding hospitals' performance The quick completion of enrollment in the Absorb randomized trials is definitely a testament to the interest among doctors and individuals in advancing new choices to treat heart disease, said Gregg Stone, M.D., FACC, FSCAI, director, cardiovascular research and education, Center for Interventional Vascular Therapy, Columbia University Medical Center, New York-Presbyterian Medical center.The analysis of data from 188 countries found that life span for both sexes increased from just over 65 years in 1990 to 71.5 years in 2013, while healthy life span rose from almost 57 years to slightly more than 62 years. The findings regarding healthy life expectancy versus total life span mean that people are living more years with illness and disability, based on the authors of the scholarly study published Aug. 27 in The Lancet. ‘The world has produced great improvement in health, but now the problem is to purchase finding more effective ways of preventing or treating the major causes of illness and disability,’ study writer Theo Vos, a professor at the Institute for Health Metrics and Evaluation at the University of Washington in Seattle, said in a journal news launch.